文献速递骨质疏松与代谢性骨病创伤骨科脊柱外科

糖皮质激素治疗初始90天内的平均每日剂量、处方天数及累积剂量与后续髋部及临床椎体骨折风险相关:基于日本全国健康保险索赔数据库的回顾性队列研究

Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.
PubMed 文献 · Osteoporos Int · 2024-01-24

研究基于日本全国健康保险索赔数据库,纳入初始90天内接受糖皮质激素(≥70 mg泼尼松龙等效剂量)且年龄≥50岁的患者,随访后续1080天髋部和临床椎体骨折发生率。结果显示初始90天糖皮质激素暴露与骨折风险呈剂量依赖性相关,且较低日剂量、较短疗程即可显著增加骨折风险。

要点

  • 初始90天糖皮质激素暴露与髋部和临床椎体骨折风险呈剂量依赖性相关。
  • 在处方30-59天层中,接受≥5 mg泼尼松龙/日者骨折风险显著增加。
  • 女性接受≥1且<2.5 mg泼尼松龙/日共90天者骨折风险亦显著增加。

核心结论

  • 糖皮质激素治疗初始90天暴露与髋部和临床椎体骨折风险呈剂量依赖性相关。
  • 糖皮质激素可能在比既往报告更低的剂量和更短的疗程下即增加骨折风险。

研究设计与样本

  • 基于日本全国健康保险索赔数据库(NDBJ)的回顾性队列研究。
  • 从NDBJ中选取年龄≥50岁、初始90天内处方糖皮质激素(≥70 mg泼尼松龙等效剂量)并随访后续1080天髋部和临床椎体骨折发生率的患者。
  • 采用Cox回归分析评估糖皮质激素暴露与髋部或临床椎体骨折风险的关联,并校正潜在混杂因素。

主要发现

  • 糖皮质激素暴露组纳入316,396名女性和299,871名男性,参考组纳入43,164名女性和33,702名男性。
  • 初始90天内较高的糖皮质激素剂量和较长的处方天数与骨折风险增加显著且呈剂量依赖性相关(相对于参考组)。
  • 在处方30-59天层中,接受≥5 mg泼尼松龙/日者骨折风险显著增加。
  • 女性在初始90天内接受≥1且<2.5 mg泼尼松龙/日共90天者骨折风险显著增加。

临床怎么用

  • 原文推荐在糖皮质激素治疗开始后三个月进行骨折风险评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fracture risk assessment is recommended at three months after glucocorticoid (GC) therapy initiation. This study aimed to assess whether GC exposure in the initial 90 days of GC therapy is associated with subsequent hip and clinical vertebral fracture risk using the nationwide health insurance claims database of Japan (NDBJ). METHODS: Patients aged ≥ 50 years who were prescribed GC (≥ 70 mg prednisolone or equivalent; PSL) in the initial 90 days of GC therapy and were followed for hip and clinical vertebral fracture incidences for the subsequent 1080 days were selected from NDBJ. Associations of GC exposure with hip or clinical vertebral fracture risk were evaluated by Cox regression analysis adjusted for potential confounders. RESULTS: We selected 316,396 women and 299,871 men for the GC-exposed group and 43,164 women and 33,702 men for the reference group. Higher GC doses and longer prescription days in the initial 90 days of GC therapy were significantly and dose-dependently associated with increased fracture risk relative to the reference group. Patients receiving GC ≥ 5 mg PSL/day had a significantly increased fracture risk in the stratum of 30-59 days of GC prescription. In addition, female patients who received GC (≥ 1 and < 2.5 mg PSL/day) for 90 days in the initial 90 days of GC therapy had a significantly increased fracture risk. CONCLUSIONS: GC exposure in the initial 90 days of GC therapy was dose-dependently associated with hip and clinical vertebral fracture risk. GC may increase fracture risk with lower doses for shorter durations than previously reported. Fracture risk assessment three months after glucocorticoid (GC) therapy initiation is recommended. We found that GC exposure in the initial 90 days of GC therapy at lower daily doses for shorter durations than previously reported were significantly and dose-dependently associated with fracture risk using a nationwide health insurance claims database.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Iki M, Fujimori K, Nakatoh S, et al. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan. Osteoporos Int. 2024. PMID: 38267664. doi:10.1007/s00198-024-07023-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。